ideasIdea
Pharmacist interaction check before every oral cancer-drug prescription
Cancer pills interact with many common medicines for heart, stomach and blood conditions, sometimes dangerously. A pharmacist check before starting, and at each refill, would prevent avoidable harm.
Oral kinase inhibitors, CDK4/6 inhibitors, and hormonal agents have clinically significant interactions with proton pump inhibitors, anticoagulants, statins, and antiarrhythmics, and are increasingly prescribed to older multimorbid patients. Studies find potential interactions in a large proportion of such patients. A mandatory oncology pharmacist review at initiation and dose change, with a structured monitoring plan, would catch these systematically.
Hypothesis
Mandatory pharmacist review will reduce clinically significant drug interactions at initiation by at least 70% and reduce interaction-related adverse events and dose interruptions.
Rationale
Pharmacist review is the established safeguard for intravenous chemotherapy; oral agents escaped it because they are dispensed like ordinary prescriptions.
What would test it
A before-and-after study across five centres with interaction rates, adverse events, and dose interruptions as endpoints.
Maturity
early clinical
Who has to act
clinic
Cost to try
Small (under $1M)
Years to first evidence
1
Bottlenecks it attacks
- Older and multimorbid patients are excluded and undertreated · Most people with cancer are over 65 but most trial patients are younger and fitter. We guess how to treat the majority.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.